Potential $20 Billion Impact on Medicare Drug Costs by 2025?

Tablet displaying "Medicare" next to medical equipment.

The Biden-Harris administration’s Medicare drug plan could cost taxpayers over $20 billion by 2025, according to a recent Congressional Budget Office (CBO) report, raising concerns about its financial sustainability and effectiveness.

At a Glance

CBO estimates Biden-Harris Medicare drug plan could cost over $21 billion in three years
Program aims to lower seniors’ premiums, which increased due to previous Democrat policies
Critics call it a temporary fix to cover up consequences of the Inflation Reduction Act
Federal Medicare Part D spending projected to increase by $10-$20 billion in 2025

CBO Report Reveals Costly Medicare Drug Plan

The Congressional Budget Office has released a report analyzing the Biden-Harris administration’s Medicare Part D Premium Stabilization Demonstration Program. The findings suggest that this initiative could cost taxpayers over $21 billion over the next three years. This analysis was requested by several Republican members of Congress, including Senators Chuck Grassley and Jodey Arrington, who have expressed concerns about the program’s financial implications.

The program’s primary goal is to lower seniors’ premiums, which have increased due to previous Democrat policies. However, critics argue that this is merely a temporary solution to mask the consequences of the Inflation Reduction Act, which led to increased Medicare prescription drug plan premiums.

Projected Increase in Federal Spending

The CBO projects a significant increase in federal Medicare Part D spending, estimating a rise of $10 to $20 billion by 2025 due to the Inflation Reduction Act. Additionally, the demonstration program itself is expected to add $5 billion to federal spending and increase net spending on interest by $2 billion.

“Rather than coming to the table and legitimately addressing its partisan mistakes, the Biden-Harris administration threw taxpayer dollars at the problems it created, putting Americans on the hook for tens of billions more dollars.” stated Grassley

The program’s structure increases plans’ expected benefit payments, leading to higher bids and premiums for beneficiaries. It provides taxpayer-funded payments to Medicare prescription drug plans to cover costs that enrollees would otherwise pay, effectively shifting the financial burden to the federal government.

Criticism and Concerns

Critics of the program, including Republican lawmakers, have voiced their concerns about its financial implications and timing. Some view it as an election-year tactic to appease seniors and cover up the negative consequences of previous healthcare policies.

“As predicted, the Biden-Harris Inflation Reduction Act not only quelled investment for new cures, but caused Medicare prescription drug plan premiums to skyrocket, and Democrats are scrambling to cover it up before the election. In July, the Biden-Harris CMS scrambled to create a new federal program that will send billions of tax dollars to large health insurance companies to cover up a massive flaw in their so-called Inflation Reduction Act,”

The Wall Street Journal Editorial Board has even gone so far as to label the demonstration a “Medicare election bribe for seniors,” highlighting the political implications of the program’s timing and structure.

Administration’s Defense and Future Plans

Despite the criticism, the Biden-Harris Administration maintains that their policies will ultimately lead to lower drug costs for seniors. They have announced new, lower prices for 10 drugs selected for Medicare negotiations, which will take effect from January 1, 2026. These negotiated prices offer discounts ranging from 38% to 79% off list prices, with estimated savings of $1.5 billion in out-of-pocket costs for Medicare users in 2026.

“Americans pay too much for their prescription drugs. That makes today’s announcement historic. For the first time ever, Medicare negotiated directly with drug companies and the American people are better off for it,” said U.S. Department of Health and Human Services (HHS) Secretary Xavier Becerra

The administration plans to continue negotiating prices for up to 15 more drugs for 2027 and up to 20 more each year thereafter. They also point to other benefits of the Inflation Reduction Act, such as the $2,000 out-of-pocket cap for Medicare Part D enrollees starting next year. However, the long-term financial implications of these policies remain a subject of debate and concern among lawmakers and healthcare experts.